BioSpace News Archive

Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $11.50 per share.

Certara®, the global leader in model-informed drug development, regulatory science, real-world evidence and market access services, today announced that Brazil’s National Health Surveillance Agency (ANVISA), Japan’s Pharmaceuticals and Medical Device Agency (PMDA), and the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) are increasing their adoption of Certara’s Phoenix® software to evaluate drug regulatory submissions.

Continued support of existing investors will fund commercialization efforts, product launch later this year

Roche presents data from a mock clinical trial study suggesting that next-generation discovery proteomics is ready for use in clinical trials.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that the Company completed an at-the-market offering for $5.3 million in gross proceeds, with insiders responsible for supporting over 37% of the raise.

National Prosthodontics Awareness Week, April 7-13, highlights restoring healthy smiles

4Front Holdings, LLC, a leading U.S. cannabis retail and brand development company, is pleased to announce the proposed board of directors of the new public 4Front company that will survive after the completion of its planned business combination with Cannex Capital.

DocuSol® Kids mini-enemas are often used by parents dealing with children who routinely avoid using the bathroom and become constipated.

New feature helps clinical trial research sites and sponsors more accurately and efficiently achieve IRS tax compliance while maintaining confidentiality and privacy

The adoption of a unique combination of the best in science and health technology such as genomics, biomarkers and companion technologies are expected to be the biopharmaceutical industry’s new growth machine, according to new research from Accenture (NYSE: ACN).